MAT

Discovery Behavioral Health Appoints Derek Wilksen as CEO of Authentic Recovery Center in West L.A.

Retrieved on: 
Wednesday, July 27, 2022
Serenity, ACT, ARC, Happiness, Boys & Girls Clubs of America, TMS, Lists of diseases, Psychiatry, CEO, MAT, Evidence-based medicine, Marketing, Cognitive behavioral therapy, California State University, CBT, Hospital, Eating disorder, Mental health, DBT, Patient, Topical steroid withdrawal, Depression, Addiction medicine, Anxiety, Pharmaceutical industry, Management, Discovery

LOS ANGELES, July 27, 2022 /PRNewswire/ -- Discovery Behavioral Health, Inc ., an expanding network of evidence-based mental health, substance use and eating disorder treatment centers, has appointed David Wilksen as CEO of Authentic Recovery Center (ARC) in West Los Angeles.

Key Points: 
  • LOS ANGELES, July 27, 2022 /PRNewswire/ -- Discovery Behavioral Health, Inc ., an expanding network of evidence-based mental health, substance use and eating disorder treatment centers, has appointed David Wilksen as CEO of Authentic Recovery Center (ARC) in West Los Angeles.
  • Wilksen is an experienced marketing and business consultant with an additional background in behavioral health center management.
  • Previously, he served as Executive Vice President of Serenity Lodge Addiction Treatment Center in Lake Arrowhead in Southern California.
  • That's why Discovery Behavioral Health has made evidence-based, outcome driven healthcare accessible and affordable since inception.

Bicycle Health Joins Forces with Included Health to Help More Patients Access Opioid Use Disorder Treatment

Retrieved on: 
Tuesday, July 26, 2022
Conditional sentence, GLOBE, Insurance, Industry, CEO, MAT, Opioid use disorder, COVID-19, OUD, Workplace, Johns Hopkins Bloomberg School of Public Health, Patient, Health, Housing, Program, Addiction, Medication, Bicycle, Public health, Pharmaceutical industry, Health insurance, Hospital

BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Bicycle Health , the leading provider of virtual opioid addiction treatment, today announced a collaboration with Included Health the only integrated clinical care and healthcare navigation platform to help patients discover and navigate Bicycle Healths treatment options and seek treatment for their opioid use disorder (OUD).

Key Points: 
  • BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Bicycle Health , the leading provider of virtual opioid addiction treatment, today announced a collaboration with Included Health the only integrated clinical care and healthcare navigation platform to help patients discover and navigate Bicycle Healths treatment options and seek treatment for their opioid use disorder (OUD).
  • As part of this collaboration, Included Health will direct eligible members in need of OUD care to Bicycle Health through a seamless transfer of relevant medical information and context.
  • This epidemic is rampant and widespread but treatment is often limited and ineffective, said Ankit Gupta, CEO and founder of Bicycle Health.
  • Opioid use disorder is an urgent issue in our country today, said Nupur Srivastava, Chief Product Officer for Included Health.

Mattel Announces Multi-Year Agreement with SpaceX to Produce Toys and Collectibles

Retrieved on: 
Wednesday, July 20, 2022
Toys, Entertainment, Family, Consumer, Parenting, Retail, Children, Science, Licensing (Entertainment), Aerospace, Manufacturing, Other Science, SpaceX, MAT, Partnership, Family, Multimedia, NASDAQ, Phillumeny, Mattel Inc v 3894207 Canada Inc, Television, Music, Toy, Mattel

View the full release here: https://www.businesswire.com/news/home/20220720005304/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220720005304/en/
    In 2023, Mattel will begin releasing SpaceX-inspired toys under its iconic Matchbox brand.
  • Simultaneously, astro-inspired collectibles will start to debut on Mattel Creations, Mattels collaboration and direct-to-consumer platform.
  • We take pride in our ability to create products and experiences that honor cultural moments and inspire humankind, said Nick Karamanos, SVP Entertainment Partnerships at Mattel.
  • We look forward to working with Mattel to help inspire the next generation of space explorers and enthusiasts."

Cordant Health Solutions Opens 10,000-Square-Foot Pharmacy Location in Louisville, Kentucky, to Serve Midwest and Southeast

Retrieved on: 
Wednesday, July 20, 2022
People, Patient, Society, Specialty pharmacy, GLOBE, ACHC, White, HCV, Commonwealth, Naloxone, MAT, SUD, CEO, Electronic Healthcare Network Accreditation Commission, Addiction, Solution, Pharmacy, Health, Risk, Conditional sentence, Family, Safety, Pain management, Risk assessment, Substance use disorder, White House, Hepatitis, Addiction medicine, American Society of Addiction Medicine, Organization, Quality of life, Prescription, Journal, Transport, URAC, ASAM, HIV, Hospital, Pharmaceutical industry, St. Matthew's

The new location houses Cordant's two pharmacy brands, St. Matthews Community Pharmacy and St. Matthews Specialty Pharmacy, and serves as the hub for pharmacy operations in the Midwest and Southeast.

Key Points: 
  • The new location houses Cordant's two pharmacy brands, St. Matthews Community Pharmacy and St. Matthews Specialty Pharmacy, and serves as the hub for pharmacy operations in the Midwest and Southeast.
  • Cordant acquired St. Matthews Community and Specialty Pharmacy, a well-known and respected pharmacy in April 2021 and has since invested in St. Matthews to expand its capacity to serve patients in the Commonwealth as well as across the Midwest and Southeast.
  • To address the growing need both regionally and nationally for specialized pharmacy services for addiction treatment and behavioral health conditions, Cordant merged its existing Louisville Cordant Pharmacy Solutions location and the newly acquired St. Matthews pharmacies into the new, larger facility in February 2022.
  • People with SUD are also at particular risk for developing one or more primary conditions or chronic diseases, including hepatitis.

Preclinical Data Demonstrate Potential of Creative Bio-Peptides’ Multi-Chemokine Receptor Antagonist RAP-103 to Enhance Opioid Analgesia and Inhibit Opioid-derived Dependence, Withdrawal and Respiratory Depression

Retrieved on: 
Tuesday, July 19, 2022
Research, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Ruff, Initiative, OUD, Research, National, Acquisition, CEO, Temple University School of Medicine, Morphine, Neurodegeneration, Motivation, Safety, National Institute, Department, Therapy, Inflammation, Chemokine, NIH, Temple University, Center, Creative, Nucleus accumbens, Opioid use disorder, Maintenance, CCR2, Brain, Substance abuse, Heroin, Substance dependence, Hormone, Dementia, IND, The Center, CBP, OPRM1, National Institute on Drug Abuse, Principles of Neural Science, Pain, Substance Abuse, CXCR4, Hypoventilation, Doctor of Philosophy, Regeneration, Ventral tegmental area, Dopamine, CCR5, MAT, Neuron, Opioid, Pharmaceutical industry, Cereal, Medicine

RAP-103 also reduced the severity of naloxone-precipitated withdrawal responses in morphine dependence, as well as morphine-induced respiratory depression.

Key Points: 
  • RAP-103 also reduced the severity of naloxone-precipitated withdrawal responses in morphine dependence, as well as morphine-induced respiratory depression.
  • In addition, RAP-103 normalized the components of addiction chemistry in the brain that are altered by opioid abuse.
  • These data were published online ahead of print in the September 2022 issue of the peer-reviewed scientific journal Drug and Alcohol Dependence.
  • The results identify chemokine receptor antagonist RAP-103 as a potential treatment to enhance opioid analgesia and inhibit opioid-derived dependence, withdrawal and respiratory depression.

CODAC Announces Mobile Medical Unit Able to Dispense Methadone as Part of Full MAT

Retrieved on: 
Tuesday, July 19, 2022
Linda, OUD, Public health, MSW, Representative, CEO, Disease, Rhode Island Senate, Patient, Senate, OTP, Association, Department, RIDOC, Center, Program, Opioid use disorder, Opioid, Naltrexone, Telehealth, SAMHSA, United States drug overdose death rates and totals over time, Topical steroid withdrawal, Hope, Center of excellence, Death, Wisconsin Department of Justice, Rhode Island House of Representatives, Buprenorphine, American Association, Foundation (nonprofit), Teaching hospital, DEA, Blood pressure, Champlin Foundations, FDA, MAT, Rhode Island Department of Health, Friends, Oklahoma State Department of Health, Treatment, Justice, Pharmaceutical industry, Health insurance

CRANSTON, R.I., July 18, 2022 /PRNewswire-PRWeb/ -- CODAC Behavioral Healthcare, the largest non-profit, outpatient provider for opioid treatment in Rhode Island, today announced the launch of its new mobile medical unit that will dispense methadone along with the other two FDA-approved medications for opioid use disorder (OUD) as part of Medication-Assisted Treatment (MAT). CODAC's mobile medical unit is the first in the nation to be approved under the new DEA regulations that went into effect on July 28, 2021.

Key Points: 
  • CODAC's mobile medical unit is the first in the nation to be approved under the new DEA regulations that went into effect on July 28, 2021.
  • The mobile medical unit will begin providing MAT services, including counseling, and methadone dispensing (as well as treatment with buprenorphine and naltrexone) to patients residing in Woonsocket.
  • This new mobile medical unit from CODAC Behavioral Health does just that," said Governor Dan McKee.
  • We believe that the presence of CODAC's Mobile Medical Unit will help to improve current conditions on the ground."

DGAP-News: XPhyto Therapeutics Corp.: XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease

Retrieved on: 
Monday, July 18, 2022
OUD, Research, Adult, Mouth, COVID-19, CMI, Oral, OTCQB, Patient, CSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DSC, Buprenorphine, Inflammation, Stomatitis, Food, Tooth decay, Opioid use disorder, Marketing, Peri-implantitis, Adolescence, Degenerative disease, GERMANY, Dentistry, Infection, Sale, Company, Pain, USD, Therapy, FDA, MAT, ODF, Pharmaceutical industry, EU, BC

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / July 18, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY),(OTCQB:XPHYF), (FSE:4XT) ("XPhyto" or the "Company") is pleased to report a significant potential market opportunity for its oral dissolvable ("ODF") biosensor screening tests for oral inflammation.

Key Points: 
  • VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / July 18, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY),(OTCQB:XPHYF), (FSE:4XT) ("XPhyto" or the "Company") is pleased to report a significant potential market opportunity for its oral dissolvable ("ODF") biosensor screening tests for oral inflammation.
  • XPhyto is investigating the potential application of one or more of its ODF biosensor screening tests for oral inflammation to detect buprenorphine-related dental problems.
  • The Company's oral dissolvable inflammation screening test was EU registered in late 2021 and is currently licensed for marketing and sale in Europe.
  • The Company is currently investigating the potential application of one or more of its oral health biosensor screening tests for the detection of buprenorphine-related dental problems.

Quit Genius Becomes The First Substance Use Disorder Treatment Provider To Put 100% of Fees at Risk, Guaranteeing Performance and Value For Virtual Addiction Treatment

Retrieved on: 
Wednesday, July 13, 2022
Opioid addiction treatment in United States prisons, Method, GLOBE, MAT, SUD, Randomized controlled trial, Evidence-based practice, Opioid, Nicotine, Pharmacy, Risk, Workplace, Program, CEO, Pharmaceutical industry, Health insurance

Quit Genius, which sells to employers and health plans, is the first provider in its category to move to a fully at-risk pricing model.

Key Points: 
  • Quit Genius, which sells to employers and health plans, is the first provider in its category to move to a fully at-risk pricing model.
  • Previously, Quit Genius offered 50 percent fees at risk, alongside a bundled case rate fee.
  • Now, if Quit Genius misses performance goals, clients are eligible to receive up to 100 percent of the total fees paid.
  • Performance guarantees are measured annually, but clients also receive quarterly performance updates to measure whether Quit Genius is on-track to meet them.

Recovery Centers of America Opens New Outpatient Treatment Center In Malvern, Pennsylvania To Treat Mental Health Conditions --

Retrieved on: 
Wednesday, July 13, 2022
Mirror Lake Recovery Center, Anxiety, Trauma, National Alliance, Joint Commission, Program, Personality, Patient, RCA, Lists of diseases, Addiction, United States Public Health Service, Bipolar disorder, Depression, Mental disorder, Mental health service, Mental health, National Alliance on Mental Illness, MAT, Devon, DNA, Medicine, Pharmaceutical industry, Health insurance

MALVERN, Pa. , July 13, 2022 /PRNewswire/ -- At a time when mental health issues are on the rise around the United States across all ages and demographic groups, Recovery Centers of America (RCA) at Devon is stepping up to meet the increased need for mental health services by opening a new, larger Mental Health Outpatient Treatment Center in neighboring Malvern, Pa. that can assist patients all over Pennsylvania.

Key Points: 
  • "We have been treating mental health as a primary diagnosis at Devon, but we outgrew our facility.
  • RCA Outpatient at Malvern's expanded mental health treatment program is available now to individuals across Pennsylvania who have a mental health condition as a primary diagnosis.
  • For patients who need mental health outpatient treatment and are not located close to Malvern, RCA's structured mental health treatment program is accessible virtually.
  • Recovery Centers of America is dedicated to helping patients achieve a life of recovery through evidence-based alcohol and drug addiction treatment and mental health care.

Pinnacle Treatment Centers to Build Drug and Alcohol Detox Program at IU Health Morgan

Retrieved on: 
Thursday, July 7, 2022
Mental Health, Hospitals, Health, University, Education, Patient, CEO, US Market Access Center, Health, Hospital, Indiana University School of Medicine, Passages Malibu, Desert Hope Addiction Treatment Center, Â, Pinnacle, Partnership, IU, Opioid use disorder, MAT, DNP, RN, Indiana University Health, Bed, Mental health, Program, Stepping, Residential care

Pinnacle Treatment Centers , a leader in providing affordable, accessible treatment for adults struggling with substance use issues, is jumpstarting the development of a withdrawal management (detox) unit at Indiana University Health Morgan in Martinsville, IN.

Key Points: 
  • Pinnacle Treatment Centers , a leader in providing affordable, accessible treatment for adults struggling with substance use issues, is jumpstarting the development of a withdrawal management (detox) unit at Indiana University Health Morgan in Martinsville, IN.
  • Pinnacles unit, named Recovery Works Morgan, will be dedicated to comprehensive care for patients needing assistance with drug and/or alcohol addiction.
  • Jason King, DNP, RN, CENP, FAONL, chief operating officer and chief nursing officer at IU Health Morgan, said, IU Health wants to make Indiana a healthier state, and mental health and addiction recovery are an integral part of that goal.
  • Construction at IU Health Morgan is slated to begin in July with the program opening by end of 2022.